Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease

#Immunovant shares were sliding today after it reported that FcRn blocker #batoclimab failed a pair of phase 3 trials in thyroid eye disease.

Purcell & Lefkowitz LLP Launches Investigation into Immunovant, Inc. Shareholder Activity Purcell & Lefkowitz LLP has initiated an investigation regarding Immunovant, Inc., focusing on potential breaches of fiduciary duty by its directors, affecting shareholders' interests.

Purcell & Lefkowitz LLP Launches Investigation into Immunovant, Inc. Shareholder Activity #United_States #New_York #Shareholder_Rights #Purcell_&_Lefkowitz #Immunovant

Investigation Launched into Immunovant by Kahn Swick & Foti Law Firm Kahn Swick & Foti, LLC has initiated an investigation into Immunovant, Inc., examining potential breaches of duty by its officers and directors.

Investigation Launched into Immunovant by Kahn Swick & Foti Law Firm #United_States #Kahn_Swick_&_Foti #New_Orleans #Immunovant #Legal_Investigation

Investigation Launched Into Immunovant's Private Placement Transaction: What Investors Should Know The law firm Robbins Geller has initiated an investigation into Immunovant's recent private placement transactions, urging investors to connect.

Investigation Launched Into Immunovant's Private Placement Transaction: What Investors Should Know #United_States #Robbins_Geller #San_Diego #Immunovant #Roivant_Sciences

Purcell & Lefkowitz LLP Launches Shareholder Investigation into Immunovant, Inc. Purcell & Lefkowitz LLP is investigating Immunovant, Inc. to determine if its directors breached fiduciary duties. Shareholders can learn their options.

Purcell & Lefkowitz LLP Launches Shareholder Investigation into Immunovant, Inc. #USA #New_York #Shareholder_Rights #Purcell_&_Lefkowitz #Immunovant

Kuehn Law's Investigation into Immunovant, Inc. Sparks Shareholder Action Kuehn Law is investigating potential breaches by Immunovant officers and directors. Shareholders may seek damages and reforms.

Kuehn Law's Investigation into Immunovant, Inc. Sparks Shareholder Action #USA #New_York #Shareholders #Kuehn_Law #Immunovant